Pharma sector stocks to buy: A Trump tariff tantrum-proof sector? 8 stocks from pharma sector, where Democrats and Republicans are in agreement, with an upside potential of up to 34% in 1 year

[hfe_template id='11223'] [ad_1]

Synopsis

When Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who think India will be unaffected, just do a Google search for “Trump on high import duty on Harley Davidson bikes”. A further indication came just a few days ago when he mentioned Brazil and India in the same breath, saying that the two countries were imposing high tariffs and should expect consequences. While it may not become a major issue, there may well be some retaliation. Or the threat of retaliation could be used as a tool to get India to change its stance on some global issue. Or as a quid pro quo: For instance, a push for lower duties on EVs, especially cars – a move that could help Trump’s biggest backer Elon Musk and his Tesla. But one sector which would be relatively safe could be pharma, and there are reasons for it. And mind you, we are using the word “relatively”.

As the world gets ready for the start of the second term of Donald Trump, it is better to visit recent history because it is very likely that some of the statements he has made earlier will be heard once again. One should, however, be ready to make a distinction between reality and rhetoric. But remember that reality and rhetoric can have different meanings at different times. Just as an example, exactly eight years ago, in 2016, when a reality

ETMarkets.com

11 mins read, Last Updated:
  • FONT SIZE

    AbcSmall

    AbcMedium

    AbcLarge

  • SAVE
  • PRINT
  • COMMENT

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

[ad_2] Source link https://mrgaga.in/pharma-sector-stocks-to-buy-a-trump-tariff-tantrum-proof-sector-8-stocks-from-pharma-sector-where-democrats-and-republicans-are-in-agreement-with-an-upside-potential-of-up-to-34-in-1-year/?feed_id=45349&_unique_id=676510de2b65d

Comments

Post a Comment

Popular posts from this blog

India VIX jumps 100% in one month. Could fear levels take Nifty further down?

Image
[hfe_template id='11223'] [ad_1] Volatility in Indian equity markets has surged sharply over the past month, with the India VIX nearly doubling as geopolitical tensions and global uncertainty triggered aggressive selling in equities. India VIX, often referred to as the market’s fear gauge, has jumped close to 100% over the past month, reflecting growing nervousness among investors. The spike has coincided with a sharp correction in the broader market, with the Nifty 50 declining about 8% during the same period. The escalation of tensions involving the United States, Israel and Iran has intensified market anxiety in recent days, pushing crude oil prices sharply higher and triggering a global risk-off sentiment. However, analysts note that volatility had already been building even before the conflict escalated, reflecting broader concerns around global growth, foreign capital outflows and stretched valuations in equities. The heightened uncertainty translated into a sharp ...
Read more

Can Sensex, Nifty snap 2-day fall on Monday? 7 factors that could decide market mood this week

Image
[hfe_template id='11223'] [ad_1] Benchmark indices Sensex and Nifty ended the week on a bearish note, closing over a percent lower each as a deepening selloff in IT stocks rattled investor sentiment amid mounting fears of AI-led disruption. Further, stronger-than-expected jobs data for January dampened hopes of a US Fed interest rate cut. Here are 7 factors that could decide market action in the coming week: 1.) Infosys, Wipro ADRs rebound - After a brutal two-day selloff that saw Infosys and Wipro ADRs plunge as much as 14.5%, Friday’s session brought a much-needed breather. Bargain hunting kicked in at lower levels, sparking a sharp rebound as Infosys climbed 3% while Wipro gained 4%—helping both stocks close the week on a far stronger note. International brokerage firm JP Morgan has a message for panic-stricken investors: IT services firms are the indispensable "plumbers of the tech world" and their dividend yields have now hit levels last seen only during ...
Read more

Waaree Energies shares in focus after Q4 profit rises 34% to Rs 619 crore, revenue up 36%

Image
[hfe_template id='11223'] [ad_1] Waaree Energies shares will be in focus on Wednesday after the solar panel maker reported a strong Q4 performance, with net profit rising 34.1% year-on-year (YoY) to Rs 618.9 crore for the quarter ended March 31, 2025. In the same quarter last year, the company had reported a profit of Rs 461.5 crore. Revenue from operations jumped 36.4% to Rs 4,003.9 crore, up from Rs 2,935.8 crore in the year-ago period, according to the company’s regulatory filing. EBITDA more than doubled to Rs 922.6 crore in Q4 FY25, up 120.6% from Rs 418.3 crore in the same quarter last year. The EBITDA margin improved to 23% from 14.3% a year ago. The company produced 2.06 GW of solar modules in the fourth quarter, up from 1.35 GW in the same period last year. For the full year, module production reached 7.13 GW, compared to 4.77 GW in FY24. For the full financial year FY25, revenue rose 27.62% YoY to Rs 14,846.06 crore. Profit after tax more than doubled to Rs 1,9...
Read more